- Home
- BLDR vs SYRE Comparison
BLDR vs SYRE Comparison
Compare BLDR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLDR | SYRE |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.5B |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BLDR | SYRE |
|---|---|---|
| Price | $81.12 | $87.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | ★ $121.76 | $85.08 |
| AVG Volume (30 Days) | ★ 2.2M | 925.2K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $0.71 | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $65.10 | $14.49 |
| 52 Week High | $151.03 | $90.99 |
Technical Indicators
Market Signals| Indicator | BLDR | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 69.35 |
| Support Level | $78.25 | $66.78 |
| Resistance Level | $130.47 | N/A |
| Average True Range (ATR) | 3.74 | 4.83 |
| MACD | 0.78 | 1.19 |
| Stochastic Oscillator | 81.27 | 88.22 |
Price Performance
Historical ComparisonAbout BLDR Builders FirstSource Inc.
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.